Introduction {#sec1_1}
============

Colorectal cancers (CRC) are the second most frequent malignancy for both males and females in Germany, affecting 6% of the population. Of these, 65% are sporadic, 25% familial of polygenic origin, and 5-10% pertain to an autosomal dominant mode of inheritance. In this last group, the most frequent hereditary predisposition is Lynch syndrome, accounting for 3-5% of all CRC \[[@B1]\].

Hereditary Non-Polyposis Colorectal Cancer/Lynch Syndrome {#sec1_2}
=========================================================

Lynch syndrome is defined as the detection of a pathogenic mutation in one of the so-called mismatch repair (MMR) genes after exclusion of a BRAF mutation. Hereditary non-polyposis colorectal cancer (HNPCC) is defined through the fulfillment of the Amsterdam criteria based on the family cancer pedigree information by taking CRC and other extracolonic cancers as well as age at diagnosis into account. HNPCC or Lynch syndrome must be suspected if microsatellite instability (MSI) using the PCR-based method is detected, or if a loss of protein expression in one of the MMR genes is identified immunohistochemically either in the biopsy or in the tumor specimen. However, methylation of hMLH1 must be excluded if the loss of protein expression occurred in MLH1. After detection of MSI or MMR loss of protein expression, testing for a germline mutation in one of the MMR genes in a blood sample should be performed, obviously after obtaining 'informed consent'. The detection of a germline mutation in an index patient enables predictive testing for relatives interested in this option and should be embedded in genetic counseling.

On a clinical level, HNPCC/Lynch syndrome leads to a high predisposition for colorectal, gynecological, and other tumors (table [1](#T1){ref-type="table"}) with lifetime risks as high as 80-90%, depending on gene and gender.

MMR genes are responsible for the identification and repair of nucleotide mismatches that may occur during DNA replication. Of the known MMR genes (MSH2, MLH1, MSH6, MSH3, PMS1, PMS2), mutations have been reported to occur predominantly in either the MSH2 or MLH1 genes in 90% of the cases \[[@B2],[@B3]\]. This may, however, be caused by selection bias since these genes were the first identified and, as a result, most patients have been subjected to an analysis of these and not usually to all four of the routinely recommended MMR genes today, i.e. hMSH2, hMLH1, hMSH6, and PMS2. The role of a mutation in the EPCAM region, which is located before the MSH gene and which can lead to an inactivation of MSH2, is still unclear \[[@B4]\]. However, even if this is not yet conclusively clarified, an association with Lynch syndrome has to be assumed \[[@B5]\].

Clinical screening for potential Lynch syndrome patients according to the new German S3 guidelines should still be based on the 'revised Bethesda criteria' (table [2](#T2){ref-type="table"}) \[[@B6],[@B7]\] and the Amsterdam I or Amsterdam II criteria (table [3](#T3){ref-type="table"}) \[[@B8]\]. Many countries have already established systematic tumor screening at least for CRC, some with an upper age limit of 70 years. The European (Mallorca) guidelines also recommend this approach due to an unacceptably high number of missed cases of up to 50% when identification is based on the clinical criteria. Therefore, an amendment and update of these newly published German S3 guidelines must already be taken into consideration.

Lynch syndrome was first described by the pathologist Warthin in 1895 \[[@B9]\], who identified the family of his seamstress with a high rate of gynecological cancers in association with CRC. Henry Lynch later followed up on 'Family G', and due to the high detection rate mostly of CRC in later generations he proposed the term 'hereditary non-polyposis colorectal cancer' (HNPCC). After pinpointing deficient MMR genes as the causative underlying molecular pathogenetic mechanism for the syndrome, eventually the underestimated frequency of extracolonic cancers was newly acknowledged. Families without mutation but with fulfillment of the Amsterdam criteria -- referred to as HNPCC -- differ clinically from Lynch syndrome families, especially due to a higher age of manifestation and an overall lower rate of extracolonic cancers \[[@B10],[@B11]\]. After clinical demonstration of this difference the terms HNPCC and Lynch syndrome were defined for differentiation between the two entities.

Gender Differences {#sec2_1}
------------------

Colorectal Cancer

The lifetime risk for CRC in patients with Lynch syndrome is 28-75% for males and therefore higher than in females, with an overall risk of 24-52% \[[@B7]\]. Especially in the case of MSH6 mutations a clear genotype-phenotype correlation has been established. Females with a mutation in MSH6 have a cumulative CRC lifetime risk of 30% whereas men have a risk of 54%.

The overall younger average age at manifestation of Lynch syndrome-associated CRC of 45 years is noteworthy and approximately 20 years lower than in the sporadic counterpart. However, many Lynch syndrome patients are older at the time of their first CRC diagnosis, as observed by Hampel et al. \[[@B12]\] in a study from 2005 in which the median age for the first diagnosis of a CRC in 373 family members with Lynch syndrome was 61.2 years of age. Furthermore, Lynch syndrome patients demonstrate frequent synchronous and metachronous CRC in 18% and 24-30% of all cases, respectively, at 10 years and 50% at 15 years after diagnosis of a CRC \[[@B13],[@B14],[@B15]\]. Although there is a slight right-sided predominance of the CRC, it is important to acknowledge that 20% of the index patients in Germany are diagnosed with rectal cancer \[[@B16]\].

Gynecological Cancer {#sec2_2}
--------------------

Endometrial cancer and ovarian cancers occur in female Lynch syndrome patients with a lifetime risk of 28-60% \[[@B17]\] and 6-7% \[[@B18]\], respectively. The risk for occurrence of endometrial cancer in MSH6 mutation patients may be as high as 36% until the age of 60 and 71% until the age of 70 \[[@B19]\]. In contrast to this very high cancer incidence associated with an MSH6 mutation, the risk for these cancers in Lynch syndrome patients with an MLH1 or MSH2 mutation is 'only' 24% and 37%, respectively, until the age of 70 \[[@B20]\]. Overall, the risk for endometrial cancer is substantially higher than previously recognized, and endometrial cancer should be clinically acknowledged as the second most frequent index or sentinel cancer for Lynch syndrome.

Cancer of the Urinary Tract {#sec2_3}
---------------------------

Urothelial cancers including those originating from the ureter and the renal pelvis occur 22 times more frequently in Lynch syndrome patients than in the normal population \[[@B18]\]. Males have a 1.6-fold higher risk than females whereas males with an MSH2 mutation have a lifetime risk of 6-28% while females with an MSH2 mutation have a risk of 6-12% \[[@B18]\].

Bladder Cancer {#sec2_4}
--------------

The association of bladder cancer with Lynch syndrome has been controversially discussed until today. In a recent publication, however, 71% of the observed bladder cancers occurred in patients with an MSH2 mutation, 10% had an MLH1 mutation, and 19% an MSH6 mutation. 90% (!) of the affected patients were men. The cumulative risk until the age of 70 for a Lynch syndrome-associated bladder cancer was 7.5% for males and 1% for females \[[@B21]\].

Prostate Cancer {#sec2_5}
---------------

Patients with Lynch syndrome have a cumulative risk of 30% until the age of 70 to develop a prostate cancer (population risk 8%). The age of manifestation is significantly lower than in the sporadic population with 60.4 versus 66.6 years \[[@B22]\].

Screening Recommendations {#sec2_6}
-------------------------

The recommendations following the new German S3 guideline 'Colorectal Cancer' are summarized in table [4](#T4){ref-type="table"}.

The authors suggest that it might be timely to propose gene- and gender-adapted screening recommendations for Lynch syndrome patients. The significantly higher lifetime risk and earlier age of manifestation for CRC in men and the much lower incidence of CRC in females, especially concerning those with an MSH6 mutation, should be discussed with the patients. At least until large cohorts are evaluated looking into these correlations in more detail, individual family history should also be taken into account. Along the same lines, females should always, but especially in the case of an identified MSH6 mutation, be made aware of their very high risk especially for endometrial but also for ovarian cancer. Similarly, due to the lower incidence of gastric, bladder, and urothelial cancers, females might not need to follow the stringent recommendations since they are very infrequently affected.

A gene-gender-based recommendation predicated on penetrance should be the target of large international studies such as the International Mismatch Repair Consortium (IMRC) or the Mallorca Group in order to stratify screening recommendations. Compliance of at-risk persons or mutation carriers is much lower worldwide than assumed and an educational issue of importance. However, low complication rates due to screening procedures such as colonoscopy may also be reported since they are existent and sometimes underestimated. A risk-adapted screening recommendation could be beneficial in order to increase compliance, and it may be mentioned that an awareness of physicians regarding the identification and management of patients with HNPCC and Lynch syndrome is required.

Surgery of Lynch Syndrome-Associated Cancers {#sec2_7}
--------------------------------------------

In the new German S3 guideline for 'Colorectal Cancer' from 2013 it has now (finally) become a recommendation that the option of 'prophylactically extended colon surgery' should be discussed with a patient before surgery \[[@B23]\]. Due to the substantial rate of 23.7% for metachronous CRC despite yearly screening intervals in a time period of 20 years \[[@B24]\], subtotal colectomy is the preferred type of surgery in the European, Australasian, and US setting \[[@B25],[@B26]\]. Furthermore, a large unpublished international study (Schneider C, in preparation) as well as two smaller studies demonstrated that there is no statistically significant difference in the quality of life after a segmental oncological resection or extended prophylactic surgery with subtotal colectomy. The complication rate for the standard oncological versus the extended subtotal colectomy for colon cancer is identical. Therefore, it is the authorss\' opinion that subtotal colectomy for colon cancer should invariably be discussed with the patients as an equally good option, discussing pros and cons with each patient and taking personal considerations into account (age, occupation, sphincter function, etc.).

Surgery for Gynecological Cancers {#sec2_8}
---------------------------------

In contrast to screening for CRC with an at least frequently identifiable precursor lesion, there is no evidence for a benefit of a screening program for gynecological cancers.

Prophylactic hysterectomy and adenectomy have now (finally) been recommended for females after the completion of family planning or at the age of 40. This surgery, however, is merely prophylactic and as such is recommended as a standalone procedure in the situations described above. Nevertheless, in order to spare patients the sequelae of an additional operation at the time of a CRC, this prophylactic option should be offered as a simultaneous procedure. Although no evidence has been documented, pipelle aspiration biopsy is recommended on a yearly basis for all female Lynch syndrome patients in the German guidelines. In a large study published in 2006, Schmeler et al. \[[@B27]\] found that 33% of the females that were managed by screening instead of prophylactic hysterectomy and adenectomy developed an endometrial and 5% an ovarian cancer. The value of actively suggesting the option of prophylactic gynecological surgery to female patients must be underlined and is strongly endorsed by the authors.

Familial Adenomatous Polyposis {#sec1_3}
==============================

Familial adenomatous polyposis (FAP) is caused by a mutation in the APC gene and follows an autosomal dominant mode of inheritance. It is the most frequent polyposis syndrome of the colorectum. Clinically, FAP is defined by the occurrence of more than 100 adenomas in the colorectum; left untreated, a complete penetrance of CRC is observed, since virtually all patients develop CRC. There is also an increase of duodenal cancers, with a cumulative lifetime risk of approximately 5% \[[@B28]\]. Beyond other extraintestinal manifestations that are basically not as clinically relevant such as osteomas, epidermoid cysts, and retinal alterations (congenital hypertrophy of the retinal pigment epithelium (CHRPE)), there is a somewhat increased risk of hepatoblastoma in childhood, and later in age papillary thyroid cancers and meduloblastomas also demonstrate an increased frequency. Taking gender into account, papillary thyroid cancers occur almost only in females. Also of note is that desmoid tumors (mesenteric fibromatosis) occur mainly in younger females and are much less frequent in males.

Desmoids, also termed as aggressive fibromatosis, are semi-malignant or semi-benign tumors that grow infiltrative locally, mimicking malignancy, but do not metastasize. Clinically, desmoids are categorized according to their localization into intraabdominal, extraabdominal, and abdominal wall desmoids. The clinical symptoms depend on the localization and may reach, among others, from a painless mass to a complete bowel obstruction, obstruction of the ureter, and intestinal perforation. Although sporadic desmoids are extremely rare (0.03% of all malignancies), up to 50% of all FAP patients may develop desmoids \[[@B29]\].

The risk depends both on gender and familial occurrence (2.5-fold increased risk, if a first-degree relative has a desmoid diagnosis) \[[@B30]\]. Most frequently, those families are affected that have a deleterious mutation in the APC gene beyond codon 1444 \[[@B31]\]. Therefore, the disease risk in comparison to the sporadic population is increased by the factor of 800 \[[@B32]\], although desmoids certainly remain underdiagnosed if they do not become symptomatic, or are systematically screened for.

Desmoids are the second most frequent cause of mortality after CRC \[[@B33]\]. In a sporadic population, desmoids occur in a male:female ratio of 1:1.4-1.8. However, when analyzing the desmoids of the abdominal wall the distribution rises to 1:7 \[[@B34]\]. For FAP patients, the male:female odds ratio is 1:2.1 \[[@B35]\], while in some studies with small numbers the relationship is 1:3 \[[@B36]\].

Therapeutic options for desmoids are (radical) surgical resection with a wide resection margin, radiation (50-60 Gy, as single treatment postoperatively or neoadjuvantly), chemotherapy (antracyclines, vinca alkaloids, methotrexate, dacarbazine, temozolomide), tyrosine kinase inhibitors (imatinib, sorafenib), and also non-cytotoxic medical therapies such as high-dose antiestrogens and non-steroidal anti-inflammatory drugs (NSAIDs).

The further course of desmoid patients subjected to any of the above with exception of the high-dose treatment with antiestrogens and NSAIDs is characterized by high or very high recurrence rates. These are reported to be between 30-80%, and desmoids appear to increase in their aggressive growth pattern after surgical treatment \[[@B37],[@B38]\]. This led to the recommendation of the American Society of Colon and Rectal Surgeons and the working group of the American Society of Clinical Oncology/Society of Surgical Oncology to prioritize a conservative treatment in FAP patients with intraabdominal desmoids. Both radio- and chemotherapy are described as ultima ratio in otherwise unsuccessfully treated desmoids.

Some case reports have been published on the successful administration of tyrosine kinase inhibitors. Due to the low toxicity, a therapy with imatinib may be initiated before aggressive chemotherapy is considered; however, treatment results with high-dose antiestrogens in combination with the NSAID sulindac are increasingly encouraging.

After the identification of estrogen receptor antagonists in the 1980s desmoid tumors have been treated with antiestrogens (ex iuvantibus). A study with tamoxifene and toremifene demonstrated an equal size or regression of tumor size in 65% of the patients treated \[[@B39]\]. Raloxifene showed a response mainly in postmenopausal women and a clearly better profile of side effects, especially regarding ovarian cysts. Taking into account the young age of affected FAP patients, raloxifene should be the recommended agent for female patients \[[@B40]\].

For NSAIDs, a response to therapy has been reported for different agents. Larger series of successful treatment have been reported only for sulindac. Several different strategies use combination therapies, including our own preferred regimen of combining high-dose antiestrogens with sulindac. With this standardized regimen of treatment we recently analyzed the long-term results in a series of 130 patients with FAP-associated and sporadic desmoid tumors. A statistically significant benefit of this treatment was demonstrated, especially for those patients who were not subjected to previous desmoid surgery (Quast D et al., submitted).

Based on our own as well as published data we recommend treatment of FAP-associated desmoid patients with 300 mg sulindac daily in combination with gender-specific administration of antiestrogens. High-dose tamoxifene (120 mg/day, tapering dosage) and high-dose raloxifene (240 mg/day, tapering dosage) are recommended in male and in female patients, respectively. While side effects are rarely reported for men, ovarian cysts were frequently observed in females and were of therapeutic relevance. A successful management strategy has been the puncturing of large symptomatic ovarian cysts, although their occurrence has primarily been reduced by using raloxifene.

In summary, for FAP patients, desmoids demonstrate gender-specific growth characteristics and a differing response to medical therapy. However, due to low numbers in the series and the usually retrospective data, evidence-based literature is still lacking for this aspect. Nevertheless, this regimen has found its way into the German S3 guidelines as the therapy of first choice for both sporadic and FAP-associated desmoid tumors.
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###### 

Cumulative lifetime risks of Lynch syndrome patients \[[@B41]\]

  Carcinoma                              Lynch syndrome, %   General population, %
  -------------------------------------- ------------------- -----------------------
  CRC -- males                           54--74              5
  CRC -- females                         30--52              5
  Endometrial cancer                     28--60              2
  Ovarian cancer                         6--7                1
  Gastric cancer                         6--9                \<1
  Cancer of the small bowel              3--4                \<1
  Pancreatic cancer                      \<1--4              1
  Cancer of the hepatobiliary tract      1                   rare
  Cancer of the urogenital tract         3--8                rare
  Brain cancer                           2--3                \<1
  Sebaceous skin tumor/keratoacanthoma   1--9                rare

###### 

Revised Bethesda Guidelines \[[@B6]\]; fulfillment of only one criterion necessary to warrant MSI testing

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CRC has been diagnosed before the age of 50 years.Presence of synchronous, metachronous CRC or other Lynch syndrome-associated tumors[^a^](#T2F1){ref-type="table-fn"}, regardless of age.CRC with MSI-H histology[^b^](#T2F2){ref-type="table-fn"} diagnosed in a patient who is less than 60 years of age.CRC diagnosed in a patient with one or more first-degree relatives with a Lynch syndrome-associated tumor, with one of the cancers being diagnosed before the age of 50 years.CRC diagnosed in a patient with two or more first- or second-degree relatives with Lynch syndrome-associated tumors, regardless of age.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Endometrial, stomach, ovarian, pancreas, hepatobiliary tract, small intestine, brain tumors (usually glioblastoma in Turcot syndrome), sebaceous gland adenomas, and keratoacanthomas in Muir-Torre syndrome, transitional cell carcinoma of renal pelvis or ureter.

Presence of tumor-infiltrating lymphocytes, Crohn\'s like lymphocytic reaction, mucinous/signet ring differentiation, or medullary growth pattern.

###### 

Amsterdam criteria \[[@B42], [@B43]\]; families must fulfill all criteria

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Amsterdam I criteria*
  CRC has been diagnosed in at least three relatives.One of them should be a first-degree relative of the other two.At least two successive generations are affected.At least one CRC was diagnosed before the age of 50 years.FAP has been excluded.CRC are verified by histopathological examination.
  *Amsterdam II criteria*
  Lynch syndrome-associated cancer[^a^](#T3F1){ref-type="table-fn"} has been diagnosed in at least three relatives.One of them should be a first-degree relative of the other two.At least two successive generations are affected.At least one cancer was diagnosed before the age of 50 years.FAP has been excluded.Tumors are verified by histopathological examination.
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CRC, cancer of the endometrium, small bowel, ureter, or renal pelvis.

###### 

Recommendations for surveillance in Lynch syndrome mutation carriers in the German S3 guideline \[[@B23]\]

                 Colonoscopy   Gastroscopy                           Abdominal ultrasound   Gynecology   Other                                  
  -------------- ------------- ------------------------------------- ---------------------- ------------ ------- ---- -------------------- ---- --------------------------
  S3 guideline   1             25[^a^](#T4F1){ref-type="table-fn"}   1                      35           1       25   1, TVU               25   genetic
                                                                                                                      endometrium biopsy   35   counseling with 18 years

TVU = Transvaginal ultrasound.

Or at least 5 years younger than the youngest age at diagnosis in the family.
